These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 9249034

  • 1. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).
    Wang J, Mazar A, Quan N, Schneider A, Henkin J.
    Eur J Biochem; 1997 Jul 01; 247(1):256-61. PubMed ID: 9249034
    [Abstract] [Full Text] [Related]

  • 2. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC.
    Eur J Biochem; 1997 Apr 15; 245(2):316-23. PubMed ID: 9151959
    [Abstract] [Full Text] [Related]

  • 3. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V.
    J Biol Chem; 1996 Jun 21; 271(25):14779-84. PubMed ID: 8662951
    [Abstract] [Full Text] [Related]

  • 4. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P, Wilhelm O, Oi H, Weidle UH, Goretzki L, Koppitz M, Lottspeich F, König B, Pessara U, Kramer MD.
    Biol Chem Hoppe Seyler; 1995 Oct 21; 376(10):587-94. PubMed ID: 8590627
    [Abstract] [Full Text] [Related]

  • 5. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ, Lee SW, Dichek DA, Ellis V.
    J Pept Sci; 2000 Sep 21; 6(9):432-9. PubMed ID: 11016879
    [Abstract] [Full Text] [Related]

  • 6. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V, Mukhina S, Köhler E, Resink TJ, Erne P, Tkachuk VA.
    Mol Cell Biochem; 1999 May 21; 195(1-2):199-206. PubMed ID: 10395084
    [Abstract] [Full Text] [Related]

  • 7. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S, Lockett J, Meng Y, Biliran H, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S.
    Cancer Res; 2006 Apr 15; 66(8):4173-81. PubMed ID: 16618739
    [Abstract] [Full Text] [Related]

  • 8. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
    Husain SS.
    Biochemistry; 1991 Jun 11; 30(23):5797-805. PubMed ID: 1828371
    [Abstract] [Full Text] [Related]

  • 9. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
    Wilhelm S, Wilhelm O, Schmitt M, Graeff H.
    Biol Chem Hoppe Seyler; 1994 Sep 11; 375(9):603-8. PubMed ID: 7840902
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
    Baker MS, Liang XM, Doe WF.
    Biochim Biophys Acta; 1992 Sep 15; 1117(2):143-52. PubMed ID: 1381963
    [Abstract] [Full Text] [Related]

  • 12. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N, List K, Andreasen PA, Danø K.
    Biochem J; 2003 Apr 15; 371(Pt 2):277-87. PubMed ID: 12534347
    [Abstract] [Full Text] [Related]

  • 13. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
    Behrendt N, Danø K.
    FEBS Lett; 1996 Sep 09; 393(1):31-6. PubMed ID: 8804418
    [Abstract] [Full Text] [Related]

  • 14. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
    Ellis V, Whawell SA, Werner F, Deadman JJ.
    Biochemistry; 1999 Jan 12; 38(2):651-9. PubMed ID: 9888805
    [Abstract] [Full Text] [Related]

  • 15. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE, Saunders DN, Ranson M.
    Breast Cancer Res; 2007 Jan 12; 9(1):R14. PubMed ID: 17257442
    [Abstract] [Full Text] [Related]

  • 16. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M, Ostergaard S, Hansen LB, Holm A, Danø K.
    Biochemistry; 1998 Mar 17; 37(11):3612-22. PubMed ID: 9521680
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T, Behrendt N, Ploug M.
    Stem Cells; 1997 Mar 17; 15(6):398-408. PubMed ID: 9402652
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 17; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.